The rising prevalence of chronic, deadly, and lifestyle diseases around the world, as well as the high costs associated with their cure, is driving the global generic injectables market. These medications are bioequivalent to brand-name medicines and are used as a substitute for them in the treatment of different diseases, having similar pharmacological results. When the number of patients increases, so does the use of generic injectables. They save time and offer instant relief as they are directly injected into the bloodstream. While generic injectables are more difficult to produce, their research and development costs are lower and take less time. Unlike branded drug firms, generic drug companies do not have to spend significantly on product creation and marketing. The demand for these injectables has risen as overall healthcare costs have risen sharply. Furthermore, the global generic injectables market is benefiting from the increasing preference for generic oncology drugs for treating cancer patients. The industry is being aided even more by the increasing geriatric population and growing demand for cost-effective treatment procedures, especially in emerging regions.